ROBO Global Robotics & Automation Index ETF
Exchange Traded Concepts (ROBO Global)
Tracks the ROBO Global Robotics and Automation Index — a broadly diversified, modified equal-weight basket (~90 holdings, most 1-2% each) spanning the entire robotics/automation supply chain. Deliberately not mega-cap concentrated.
Top holdings
Automated test equipment plus Universal Robots
US factory control
Precision robot-joint gears
Photonics/precision motion
Industrial robots and CNC
Surgical robotics
Performance
July 2026: 7.5% price ($85.66 Jun 30 -> $79.25 Jul 31, 2026) — Issuer, AAII, Investing.com and lazyportfolioetf all still show 6/30/2026 data (NAV YTD 22.95%, 1Y 42.96%); only stockanalysis is 7/31-stamped. YTD ~+14% is DERIVED two ways that agree: (a) 6/30 market-price YTD 23.59% chained with July -7.48%; (b) 2025 close ~$69.4 (from 2025 full-year +23.7% off $56.26) vs $79.25. Intramonth low $76.61 on Jul 29, partial bounce into Jul 31.
Recent moves
A Q2 2026 rebalance shifted the index toward 'physical AI' (reportedly adding lidar/automation names); flows up ~$225M over the past year.
Our take
The most diversified robotics basket — equal-weighting ~90 supply-chain names (top 10 only ~17%) makes it the lowest single-stock-risk way to own the theme, but the 0.95% expense ratio is the highest of the group and the breadth dilutes any single AI winner. The structural opposite of BOTZ's concentrated book.
The equal-weight rebalance is the whole fund, and it cuts both ways.
Quarterly it trims what rose and adds to what fell — structurally anti-momentum. In a theme whose returns are violently skewed (a couple of names capture most of the decade's gain), systematically capping every winner at ~2% is not risk management alone; it is paid-for downside protection whose price is forgone convexity. This is the non-leveraged analogue of the decay question: ROBO has no volatility drag from daily reset, but it does have a rebalance drag in a right-tailed theme. Second, the tent is wide. Illumina, Intuitive Surgical and industrial-automation names sit beside actual robot makers, so the basket behaves closer to global mid-cap industrial + medtech capex than to AI compute. Buyers expecting AI-adjacent beta often get an industrial cycle instead — a different risk factor with a different cycle length. Sizeable Japanese weight adds a yen/FX layer most one-line descriptions omit.
Thesis
ROBO is a bet that the robotics buildout pays the *supply chain* rather than a handful of mega-caps. Its ~91-name modified equal-weight index (holdings clustered near 1.7-1.9%; ER 0.95%, AUM ~$1.9B, inception Oct 2013) deliberately refuses concentration. That is a real, defensible position — but it is a position, not neutrality. It only wins if robotics profits diffuse across component makers, integrators and testers instead of pooling in the 3-4 names every other AI fund already owns.
Tracks the ROBO Global Robotics and Automation Index: ~91 global names across the robotics/automation value chain, tiered and modified-equal-weighted, rebalanced quarterly. Not leveraged, no daily reset, no derivatives — it is a plain long-only equity index fund. The active decision is embedded in the index: what counts as 'robotics', and the refusal to let any winner compound past ~2% of the book.
Assessment
- Lowest single-stock risk in the category: ~91 holdings, largest near 1.9%, so no one blow-up breaks the thesis.
- Owns the picks-and-shovels tier (Teradyne, Harmonic Drive, Novanta) that concentrated AI funds structurally underweight.
- Twelve-year live track record through a full boom-bust-recovery cycle — rare for a theme ETF.
- Transparent rules-based index; no manager-discretion drift between what it says and what it holds.
- 0.95% ER is roughly 2x IRBO's 0.47% and well above BOTZ's 0.68% — ~10% of a 10%/yr gross return stream, every year, compounding against you.
- 5y annualized 5.71% vs 10y 13.28% (NAV, month-end 6/30/2026): the middle of the decade was effectively lost, and that gap is the honest picture.
- Quarterly equal-weight rebalance is systematically anti-momentum in a theme with highly skewed winners.
- Theme definition is elastic — genomics and surgical-device names make this partly a medtech/industrial fund wearing a robotics label.
- Diversification across ~91 names dilutes any single breakout toward index-like returns while still charging thematic-fund pricing.
Record
The headline is a recovery that has already partly reversed. Issuer month-end NAV total returns (6/30/2026): 1y +42.96%, 3y +13.75%, 5y +5.71%, 10y +13.28%, since-inception +10.37% over ~12.7 years. Those are ~3 weeks stale: as of 7/20/2026 the trailing-1y is ~26.46% and YTD is -0.74% (stockanalysis) — ROBO has handed back much of the June-quarter surge. Read together: the 10y is respectable, the 5y (+5.71%) weak, and even the peak +43% was measured from the bottom of a multi-year drawdown, not a durable run rate. Attribution matters. The 2026 surge tracked a re-rating of industrial-automation/reshoring capex plus 'physical AI' enthusiasm — multiple expansion more than delivered earnings across the mid-cap tier, the least repeatable return source there is. The since-inception 10.37% is the number that tests the premise: owning the theme from 2013 has not been a shortcut.
Risks & fit
- Driven by the global industrial capex cycle more than by AI compute demand — a manufacturing slowdown hits it regardless of AI narrative strength.
- Heavy Japanese and non-US weight brings unhedged yen/FX and Japanese industrial-cycle exposure.
- After the 2026 re-rating (trailing-1y peaked ~+43% at 6/30, ~+26% by 7/20), entry buys an expanded multiple well off its lows, not a discount.
- Quarterly rebalance turnover creates ongoing trading costs and less tax-efficient distributions than a buy-and-hold index.
- Thematic-ETF fee compression: cheaper equal-weight rivals make 0.95% harder to defend as the category commoditizes.
If robotics profit growth keeps concentrating in a few mega-cap platforms while the mid-cap component and integrator tier posts flat-to-negative earnings revisions, ROBO's equal-weight breadth is the wrong structure and it should lag concentrated peers like BOTZ while charging more. Conversely, if 'physical AI' capex shows up in the reported P&Ls of Harmonic Drive, Teradyne and Novanta — not just in their multiples — the breadth is vindicated. Watch earnings revisions by market-cap tier, not price.
Suits an allocator wanting supply-chain-wide robotics exposure with minimal single-stock risk, who accepts a premium fee for that breadth plus unhedged Japan/FX exposure. Less aligned with someone seeking concentrated exposure to AI's largest winners (BOTZ's structure), someone fee-sensitive with the same equal-weight goal (IRBO is cheaper), or anyone treating it as a pure AI proxy — its real factor exposure is closer to global industrial capex.
0.95% ER — the highest of the major robotics ETFs, vs IRBO 0.47% and BOTZ 0.68%. On a ~10% gross annual return that fee consumes roughly a tenth of the return stream annually, and the gap vs IRBO compounds meaningfully over a decade.